Added February 4, 2013
J Clin Oncol 30: 2012 (suppl 34; abstr LBA148) In this multinational, multiinstitutional study, nab-P + G was well tolerated and superior to G with statistically significant and clinically meaningful results in all endpoints and across subgroups. Continue reading
Added January 1, 2013
J Clin Oncol. 2013 Jan 1;31(1):23-9 – FOLFIRINOX significantly reduces QoL impairment compared with gemcitabine inpatients with metastatic pancreatic cancer. Furthermore, baseline QoL scores improved estimation of survival probability when added to baseline clinical and demographic variables. Continue reading
Added July 5, 2012
Ann Oncol. 2012 Jul 5. The addition of sorafenib to gemcitabine does not improve PFS in APC patients. Continue reading
Added April 11, 2012
N Engl J Med. 2012 Apr 12;366(15):1414-1422. Among patients at high risk for post-ERCP pancreatitis, rectal indomethacin significantly reduced the incidence of the condition. Continue reading
Added October 3, 2011
J Clin Oncol. 2011 Oct 3. This trial demonstrates improved overall survival with the addition of radiation therapy to GEM in patients with localized unresectable pancreatic cancer, with acceptable toxicity. Continue reading
Added September 14, 2011
J Clin Oncol. 2011 Sep 10;29(26):3541-6. Early EUS-CPN reduces pain and may moderate morphine consumption in patients with painful, inoperable pancreaticadenocarcinoma. EUS-CPN can be considered in all such patients at the time of diagnostic and staging EUS. Continue reading
Added May 14, 2011
N Engl J Med. 2011 May 12;364(19):1817-25. As compared with gemcitabine, FOLFIRINOX was associated with a survival advantage and had increased toxicity. FOLFIRINOX is an option for the treatment of patients with metastatic pancreatic cancer and good performance status. Continue reading
Added May 14, 2011
Cancer. 2011 May 15;117(10):2044-9.This is the first population-based study to compare neoadjuvant versus adjuvant treatment strategies inresectable pancreatic cancer. Neoadjuvant therapy is associated with a lower rate of lymph node positivity and improvedoverall survival and should be considered an acceptable alternative to the surgery-first paradigm in operable pancreaticcancer. Continue reading
Added April 3, 2011
Lancet. 2011 Apr 30;377(9776):1514-22.Stapler closure did not reduce the rate of pancreatic fistula compared with hand-sewn closure for distal pancreatectomy. New strategies, including innovative surgical techniques, need to be identified to reduce this adverse outcome.
Continue reading
Added September 15, 2010
J Am Coll Surg. 2010 May;210(5):779-85, 786-7. LDP provides similar short- and long-term oncologic outcomes as compared with OD, with potentially shorter hospital stay. These results suggest that LDP is an acceptable approach for resection of PDAC of the left pancreas in selected patients. Continue reading